InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Wednesday, 09/30/2020 4:25:13 PM

Wednesday, September 30, 2020 4:25:13 PM

Post# of 85
Topline results from the Phase 2 COMPARE trial are as follows:

SEL-212 showed a numerically higher response rate on the primary endpoint during months 3 and 6 combined, but did not meet the primary endpoint of statistical superiority
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SELB News